Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Event-Driven

<ul>
<li>In May 2019, Japan’s biggest drugmaker, Takeda announced the sale of its surgical patch product, TachoSil to Johnson &amp; Johnson’s subsidiary Ethicon for a cash consideration of US$400m.</li>
<li>Ethicon will buy the assets and licenses associated with the manufacturing, licensing and commercialisation of TachoSil, but Takeda will retain the manufacturing facility in Linz, Austria.</li>
<li>Under the terms, Takeda will sign a long-term manufacturing services agreement to make and sell TachoSil products to Ethicon.</li>
<li><p>Concerned that <span>the deal could lead to reduced competition and higher prices for customers, EU antitrust regulators have opened a full investigation into the acquisition. </span></p></li>
<li>The European Commission has set an August 10 deadline for making its final decision on the deal and we believe, there is a high possibility for this deal to get approved (with or without conditions) given that even larger transactions such as AB/InBev-SABMiller and Abbvie-Allergan were approved by the commission.</li>
</ul>


In May 2019, Japan’s biggest drugmaker, Takeda announced the sale of its surgical patch product, TachoSil to Johnson &amp; Johnson’s subsidiary Ethicon for a cash consideration of US$400m.
Ethicon will buy the assets and licenses associated with the manufacturing, licensing and commercialisation of TachoSil, but Takeda will retain the manufacturing facility in Linz, Austria.
Under the terms, Takeda will sign a long-term manufacturing services agreement to make and sell TachoSil products to Ethicon.
Concerned that the deal could lead to reduced competition and higher prices for customers, EU antitrust regulators have opened a full investigation into the acquisition. 
The European Commission has set an August 10 deadline for making its final decision on the deal and we believe, there is a high possibility for this deal to get approved (with or without conditions) given that even larger transactions such as AB/InBev-SABMiller and Abbvie-Allergan were approved by the commission.


J&J’s Purchase of Takeda’s Surgical Patch Subject to EU Investigation; Expect a Deal Anyways

Japan

Takeda Pharmaceutical Company Limited is engaged in research and development, manufacturing, sales and marketing, and import and export of pharmaceutical drugs. The Company focuses on the core therapeutic areas of oncology, gastrointestinal, and central nervous system disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Takeda Pharmaceutical (TAK US)

J&J’s Purchase of Takeda’s Surgical Patch Subject to EU Investigation; Expect a Deal Anyways

In May 2019, Japan’s biggest drugmaker, Takeda announced the sale of its surgical patch product, TachoSil to Johnson & Johnson’s subsidiary...

Shifara Samsudeen, FCMA, CGMA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)